How does tesamorelin acetaat apotheek supply differ from a research CoA?
A pharmacy (apotheek) product and a research peptide lot are not interchangeable documentary objects. Pharmacy labelling is built around a registered or compounded medicine: a proprietary or generic name, a labelled amount, an expiry date, and a legal status that research reagents in Australia do not share. A research certificate of analysis is built around methods and numbers. It should state tesamorelin acetate as the chemical name, the lot identifier printed on the vial, the analytical techniques, the acceptance limits, and the measured results.
The Dutch query tesamorelin acetaat apotheek describes a procurement expectation that an Australian research catalogue cannot honestly meet as a dispensary. What it can provide is a batch pack: HPLC chromatograms, mass spectra, counterion and water-content results, and a quality sign-off trail. Laboratories that treat a research vial as if it were an apotheek pack skip identity and purity evidence tied to a lot number.
Practical discriminators include method conditions (column chemistry, gradient, detection wavelength, ionisation mode); a peak table rather than a purity adjective; concordance between vial label, CoA header and chromatogram footer; salt-form disclosure, because acetate and trifluoroacetate have different mass-balance consequences; and net peptide content for converting lyophilised powder mass into peptide mass. Those fields are not typical of a consumer-facing pharmacy label.
ClaraScience positions tesamorelin acetate as research-use material with local Australian stock, tracked dispatch and batch documentation, not as a compounding-pharmacy item. If the pack cannot show HPLC purity, intact mass and lot concordance, it does not meet a laboratory identity standard. Chemical-class literature treats tesamorelin as a synthetic growth hormone-releasing factor analogue, used here only to name the analyte class for CoA identity tests (PMID:17086939; PMID:19243281; PMID:21283099).
Which structural identifiers confirm tesamorelin as a GHRH analogue?
Identity for a research lot is not a brand name. It is a set of orthogonal observations that the solid in the vial is the intended polypeptide analogue rather than a truncated sequence, a wrong GHRH fragment, or an unrelated peptide. Published evaluations describe tesamorelin as a synthetic human growth hormone-releasing factor analogue, which fixes the chemical class under test (PMID:17086939; PMID:19243281). Independent reviews likewise treat the substance as a defined GHRH analogue rather than native GHRH (PMID:21283099; PMID:22298602).
Practical CoA markers are intact mass consistent with the expected mass of the N-terminally hexenoyl-modified chain as the free base, with adduct and charge state stated; chromatographic retention within a reference or historical-lot window; and, where available, tandem-mass fragment ions that locate the trans-3-hexenoyl moiety, the principal chemical difference from unmodified GHRH(1–44). Amino-acid analysis or nitrogen content, if present, is a content assay, not chromatographic purity.
A CoA that lists only a name and a purity percentage without method conditions is not defensible. Area-percent at one ultraviolet wavelength can hide co-eluting related substances. Intact mass as a nominal integer without charge-state assignment is equally weak. Pair reversed-phase HPLC (retention and peak table) with electrospray deconvolution, ideally including the isotopic envelope. Mass offsets of about 16 Da, 18 Da or a hexenoyl-equivalent increment should trigger a related-substances review rather than an identity pass.
Record the sequence representation, including the N-terminal modification, so later lots are comparable. Catalogue synonyms such as TH9507 must map to the same structure. This work is analyte confirmation for research reagents, not a clinical protocol.
How should acetate counterion and net peptide content be reported on a CoA?
The search string uses acetaat, the Dutch form of acetate. Tesamorelin research lots are commonly isolated as acetate salts after preparative HPLC and counterion exchange. Trifluoroacetate may remain from ion-pairing if exchange is incomplete. A pharmacy-style label that states acetate without a measured counterion percentage does not tell a laboratory how much of a weighed powder is peptide, how much is acetate, and how much is residual water or residual trifluoroacetate.
A complete research CoA reports, as separate lines, HPLC related-substances purity in area-percent; net peptide content by amino-acid analysis, nitrogen determination or a calibrated assay; acetate by ion chromatography or a validated equivalent; residual trifluoroacetate if relevant; and water by Karl Fischer titration. Peptide plus counterions plus water plus identified residuals should approach 100% within method uncertainty. HPLC purity alone causes lyophilised weigh-outs to overestimate peptide mass.
Dispensary labels often state a labelled amount on a finished pack. Research vials are lyophilised powder with a nominal fill. Without net peptide content, two lots with identical HPLC purity can contain different peptide masses per milligram of powder. Experiments normalised to peptide mass require the counterion-corrected value, not the catalogue milligram figure.
Flag mixed-salt lots. A claim of acetate with substantial residual trifluoroacetate is a different material from a fully exchanged acetate lot, both for chromatographic behaviour and for mass-balance. Name the method, the result and the limit. Cake appearance is supporting information, not a counterion assay. Salt form and net content must be read before lots are compared on a per-milligram basis.
What HPLC and intact-mass fields belong on a research lot certificate?
Reversed-phase HPLC is the workhorse purity method for synthetic peptides. For tesamorelin acetate, the CoA should state column chemistry (typically C18, with pore size and dimensions), the water–acetonitrile mobile-phase pair with a named acid or ion-pair modifier, gradient programme, flow, column temperature, detection wavelength and bandwidth, injection amount, and integration parameters used for the area-percent table. System-suitability results such as plate count, tailing and resolution belong in the same pack, because a high purity figure from an overloaded or poorly resolved run is not comparable to the same figure from a qualified method.
The peak table should list the main peak and related substances at relative retention times, with a reporting threshold. Peaks above the threshold remain unidentified if unassigned; they should not be omitted. Diode-array peak-purity data, where generated, support spectral homogeneity and do not replace mass spectrometry.
Intact-mass analysis should report instrument type, ionisation mode, observed mass-to-charge values, charge state, deconvoluted mass, and the theoretical mass, stating whether that theoretical value is free-base tesamorelin or a salt adduct. Concordance between HPLC sample identity and the mass-spectrometry sample list should be visible so spectra cannot be orphaned from the lot.
Pharmacy outer labels do not carry gradient tables; research CoAs should. If chromatograms and spectra are not provided for the same lot as the vial, the material cannot be audited. Lot identity still rests on those data, even though tesamorelin is a named analogue in the literature (PMID:21668043; PMID:27121785).
What related-substances and traceability checks should Australian laboratories file?
Purity and identity are related but not identical. A pharmacy label does not present a related-substances profile; a research laboratory should. Typical synthetic impurities for a long GHRH analogue include deletion and insertion sequences, incompletely hexenoylated material, oxidation products, aspartimide or isoaspartate where aspartic acid occurs, and residual protecting-group-related peaks. Apply a consistent reporting threshold and, above an identification threshold, a mass-to-charge value or named assignment.
Orthogonal confirmation separates a marketing purity claim from a batch record. A second HPLC method at a different pH, ion-pair or column chemistry reduces hidden co-elution risk. Mass detection on the main peak and larger related substances links the chromatogram to structure. Write numerical limits before release: minimum main-peak area-percent, maximum single unidentified related substance, maximum total related substances, with water, residual solvents and counterions specified separately.
Score Australian procurement as documentation. Confirm research-use-only status and no pharmacy or compounding claim. Match lot numbers on vial, CoA and batch report, and confirm HPLC and mass-spectral files belong to that lot. Confirm acetate reporting and net peptide content. Prefer local Australian stock and tracked dispatch so custody from warehouse to bench is reconstructable. Archive chromatogram, peak table, deconvoluted mass, counterion, water and sign-off. Overlay new HPLC traces against the previous lot rather than assuming catalogue continuity.
Defined-analogue reviews support listing impurities against a single chemical species (PMID:21668043; PMID:22298602). In an Australian research setting, the tesamorelin acetaat apotheek query is answered by that specification pack, not by a dispensary narrative.
Order Tesamorelin with documentation
If this guide helped you evaluate Tesamorelin for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Tesamorelin card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Is tesamorelin acetate supplied as an Australian apotheek product?
ClaraScience supplies tesamorelin acetate as a laboratory reagent with lot-level certificates, not as a compounded or dispensary pharmacy product. An apotheek-style label is not a substitute for HPLC, intact-mass, acetate and net-content fields. Confirm research-use-only status and lot concordance before procurement.
What identity data should a tesamorelin acetate research CoA include?
A defensible identity pack pairs reversed-phase HPLC (retention time, peak table, method conditions) with electrospray intact mass (charge state, deconvoluted mass versus the hexenoyl-modified sequence). Catalogue synonyms such as TH9507 should map to the same structure. Tandem-mass location of the N-terminal trans-3-hexenoyl moiety is supporting evidence when available.
Why does acetate versus trifluoroacetate matter on the certificate?
Acetate and trifluoroacetate are different counterions. They change mass-balance and residual ion-pair load. Net peptide content plus a counterion assay converts a lyophilised powder weigh-out into peptide mass. Mixed-salt lots should be disclosed rather than labelled as acetate by convention.
Can a pharmacy label replace HPLC-MS documentation for a research lot?
No. Pharmacy outer labels do not carry gradient conditions, related-substances tables, system-suitability results or deconvoluted masses. Those fields are the research batch record. If chromatograms and spectra are missing for the same lot as the vial, the material cannot be audited.
How should Australian laboratories trace tesamorelin acetate lots after dispatch?
Match the vial lot number to the CoA header and to HPLC and mass-spectrometry sample names. Archive PDFs of chromatogram, peak table and deconvoluted mass together with counterion and water results. Prefer local Australian stock and tracked dispatch. Treat each new lot as a new analytical object.
How should GHRH-analogue literature be used when reading a research CoA?
Use it only as a chemical-class name for the analyte you are confirming. Literature describes tesamorelin as a synthetic growth hormone-releasing factor analogue (PMID:17086939; PMID:19243281). That statement does not convert a research lot into a pharmacy product and does not imply any human-use pathway.
References
- PMID:17086939 — Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor — Curr Opin Investig Drugs — 2006
- PMID:19243281 — Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs — 2009
- PMID:21283099 — Tesamorelin — Nat Rev Drug Discov — 2011
- PMID:22298602 — Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother — 2012
- PMID:21668043 — Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs — 2011
- PMID:27121785 — Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers — Clin Pharmacol Drug Dev — 2013
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
